London, United Kingdom

Jeremy D Sanderson

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Pharmacogenetics by Inventor Jeremy D. Sanderson

Introduction

Jeremy D. Sanderson, an accomplished inventor based in London, GB, has made significant contributions to the field of pharmacogenetics with a focus on optimizing drug therapies for patients with immune-mediated gastrointestinal disorders. With a total of three patents to his name, Sanderson's work is paving the way for more personalized and effective treatment options.

Latest Patents

His latest patents include groundbreaking methods for predicting patient tolerance and optimizing drug therapy related to 6-mercaptopurine and azathioprine treatments. One of his key inventions, titled "Non-thiopurine methyltransferase related effects in 6-mercaptopurine therapy," provides methods for predicting a patient's risk of adverse drug reactions to 6-mercaptopurine by genotyping critical genes such as xanthine dehydrogenase (XDH), molybdenum cofactor sulfurase (MOCOS), and aldehyde oxidase (AOX). Additionally, the second patent, "ITPase gene polymorphisms associated with adverse drug reactions to azathioprine therapy," outlines methods for assessing a patient's risk of negative reactions to thiopurine drugs by analyzing genetic polymorphisms in the ITPA gene and determining ITPase activity levels.

Career Highlights

Jeremy Sanderson is currently employed at Guy's and St. Thomas' NHS Foundation Trust, where he collaborates with other experts to further enhance patient care through innovative research and development. His work at this prestigious institution is a cornerstone of his career, allowing him to contribute meaningfully to the medical field.

Collaborations

Throughout his career, Sanderson has worked alongside esteemed colleagues, including Anthony M. Marinaki and Melissa A. Smith. Together, they form a collaborative team that strives to improve therapeutic outcomes for patients affected by immune-mediated gastrointestinal disorders.

Conclusion

In summary, Jeremy D. Sanderson's groundbreaking inventions and collaborations underscore his dedication to advancing pharmacogenetics and optimizing treatments for patients. His innovative approaches demonstrate the importance of genetic insights in enhancing the efficacy of drug therapies, assuring a brighter future for personalized medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…